Clinical trials: Circulating Tumor Cells, CTC
Early Detection of Cancer
Culture System for Isolating Circulating Tumor Cells
This culture system utilizes the special affinity difference of biomedical material coating for different cells to achieve the effect of isolating cancer cells from the blood sample.
- Trial name
- NCT03843450
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- National Taiwan University Hospital
Locally Advanced Gastric Carcinoma
Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell
Background Local advanced gastric carcinoma (LAGC) is suggested to be potentially cured by R0 resection, and neoadjuvant chemotherapy can increase the R0 resection rate but not enough.
- Trial name
- NCT02048540
- Testing
- Bevacizumab, docetaxel oxaliplatin 5-FU CF, Gastrectomy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Chinese PLA General Hospital
Circulating Tumor Cell, HNSCC
Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer
Cancer has been a significant cause of human death in the recent two decades, although detection, diagnosis, and cancer treatments improved and evolved rapidly.
- Trial name
- NCT06755762
- Testing
- Organoid 3D culture
- Where
- Taiwan
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Healthy
Healthy Human Control Blood Collection for Validation of Biomarker Assay
Human blood will be collected to serve as control in validating clinical studies studying the detection and levels of circulating tumor cells and microvesicles in cancer patients.
- Trial name
- NCT02302885
- Testing
- Blood collection
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Gastric Cancer
Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer
To evaluate the clinical significance of cell free DNA (cfDNA) and circulating tumor cells (CTCs) in real-time monitoring the therapeutic response during HER2-targeted therapy in histologically confirmed HER2 positive…
- Trial name
- NCT02610218
- Testing
- CTC and cfDNA analysis
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Peking University
Lung Neoplasm
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Create a living biobank of PDOs from Stage I-III lung cancer patients.
- Trial name
- NCT03655015
- Testing
- Lung Tumor Resection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Anal Cancer, Locally Advanced Squamous Cell Carcinoma
Circulating Biomarkers in Patients With Anal Cancer Treated With Induction Chemotherapy
To investigate the prognostic and predictive value of plasma HPV (pHPV) prior, during and after induction chemotherapy (ICT) in locally advanced squamous cell carcinoma of the anus (SCCA) or synchronous metastatic SCCA patients…
- Conditions
- Anal Cancer, Locally Advanced Squamous Cell Carcinoma, Oligometastatic Disease, Circulating Tumor Cell
- Trial name
- NCT05233540
- Where
- 3 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Aarhus University Hospital
Non Small Cell Lung Cancer
Detecting EGFR T790M Mutations From Circulating Tumor Cells
The purpose of this research study is to determine if the EGFR mutation can be detected in CTCs. CTCs are cancer cells that are shed from solid tumors and float freely in the bloodstream.
- Trial name
- NCT01734915
- Testing
- Circulating tumor cell chip
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
Prostate Cancer Burden and Heterogeneity Evaluation Towards Liquid Biopsy: a Correlation Study to 18FDCFPyL PET and Patients Outcome
This is a prospective, monocentric, proof of concept study aims to identify in prostate cancer patients, a potential relationship between CTC-PSMA positivity and 18F-PET-PSMA results as well as patient outcome.
- Trial name
- TAYLOR (NCT06917781)
- Testing
- Patients with 18F-PET-PSMA indication
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Institut Claudius Regaud
Circulating Neoplastic Cells, Adverse Effect of Radiation Therapy
Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy
Hepatocellular carcinoma (HCC) is a common cause of cancer mortality in Asia. Most patients were presented with advanced disease.
- Conditions
- Circulating Neoplastic Cells, Adverse Effect of Radiation Therapy, Fatal Outcome
- Trial name
- NCT02066974
- Testing
- hepatoma requiring radiotherapy
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- China Medical University, China
Metastatic NSCLC, Metastatic Head and Neck Cancer
Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers
Immunotherapy is widely administrated as anticancer treatment in metastatic setting. Despite a proved efficacy in several cancer types and clinical situations, it exists a wide variability of responses in terms of efficacy and…
- Trial name
- MADMAS (NCT05091190)
- Testing
- Blood draws
- Where
- 2 sites in France
- Volunteers
- 75 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer, Immune Profile
Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy
The change of immune profiles and existence of circulating tumor cells following prostate cryotherapy may be correlated with the clinical outcome.
- Conditions
- Prostate Cancer, Immune Profile, Circulating Cancer Cells, Clinical Corelation
- Trial name
- NCT01454037
- Testing
- Prostate cryotherapy, Radical prostatectomy, Radiation
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer (EPIDROP)
The use of liquid biopsy could be the key for precision medicine. Circulating tumor cells (CTCs) are the most studied circulating biomarkers used to assess the metastatic process and they have shown their clinical validity and…
- Trial name
- EPIDROP (NCT04581109)
- Testing
- Blood sample
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Prostate Cancer, Renal Cell Carcinoma
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
This pilot study will aim to determine whether circulating tumor cells (CTCs) can be captured using the novel cMET based ferrofluid.
- Conditions
- Prostate Cancer, Renal Cell Carcinoma, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT02080650
- Testing
- Mesenchymal-marker based ferrofluid (c-MET), Epithelial cell adhesion molecule (EpCAM) ferrofluid
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Duke University
HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer…
- Conditions
- HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal Female Patients
- Trial name
- NCT02035813
- Testing
- Ribociclib, Eribulin
- Where
- Germany
- Volunteers
- 116 people
- Sponsor
- Prof. Wolfgang Janni
Circulating Tumor Cell;, Hepatocellular Carcinoma
Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence
Circulating tumour cell (CTC) count could reflect the effect of postoperative transarterial chemoembolization (TACE) on hepatocellular carcinoma (HCC) recurrence.
- Trial name
- NCT02032368
- Testing
- transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Cancer
Immune Tumor Stroma Factors and Pathologic Complete Response After Neoadjuvant Chemotherapy in Early Breast Cancer
This prospective cohort study aims to identify immune-related predictive factors of response to neoadjuvant chemotherapy in patients with early breast cancer.
- Trial name
- AKRA (NCT07407244)
- Testing
- Neoadjuvant Chemotherapy
- Where
- Slovenia
- Volunteers
- 268 people
- Sponsor
- Institute of Oncology Ljubljana
Breast Cancer, Prostate Cancer
Enumeration and Functional Analysis of Circulating Tumor Cells for Homologous Recombination: a Prospective Single-center Study on Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to is to evaluate whether a correlation exists between functional HR status/CTC enumeration in expanded CTCs measured before treatment initiation, and Progression Free Survival (PFS) under PARPi…
- Conditions
- Breast Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- E-FACTOR (NCT07555600)
- Testing
- blood sampling, Tumor sampling
- Volunteers
- 300 people
- Sponsor
- Centre Leon Berard
Circulating Tumor Cell, Gastrointestinal Cancer
EUS Guided HVA and PVA for Circulating Tumor DNA in Patients
The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of technologies for ctDNA analysis have presented an attractive opportunity for minimally invasive "liquid biopsy" genomic diagnostics.
- Trial name
- NCT04782557
- Testing
- EUS-guided portal vein and hepatic vein aspiration
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Non Small Cell Lung Cancer
A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells
Early non-small cell lung cancer (NSCLC), treated by surgery or radiotherapy in the case of inoperability, relapses in almost 50% of cases.
- Trial name
- LUNGadenosine (NCT05648188)
- Testing
- Sample
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire de Nice